Development and validation of a quantitation assay for fluorescently tagged HIV-1 virus-like particles

Journal of Virological Methods

Volumn 193, Issue 1, 2013, Pages 85-95

  Gutiérrez Granados, Sonia ^a   Cervera, Laura ^a   Gòdia, Francesc ^a   Carrillo, Jorge ^b   Segura, María Mercedes ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Fluorescently tagged virus; Fluorometry; Gag GFP; HIV 1 VLPs; Quantitation assays; Virus like particles (VLPs)

Indexed keywords

ANTIGEN P24; GAG PROTEIN; GLYCOPROTEIN; GREEN FLUORESCENT PROTEIN; NANOPARTICLE; VIRUS RNA;

ACCURACY; ARTICLE; ASSAY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DENSITOMETRY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATION ASSAY; SPECTROFLUOROMETRY; TRANSMISSION ELECTRON MICROSCOPY; VALIDATION STUDY; VIRUS PARTICLE;

FLUORESCENTLY TAGGED VIRUS; FLUOROMETRY; GAG-GFP; HIV-1 VLPS; QUANTITATION ASSAYS; VIRUS-LIKE PARTICLES (VLPS);

FLUOROMETRY; GREEN FLUORESCENT PROTEINS; HIV-1; HUMANS; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; VIRAL LOAD; VIROSOMES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84879141055     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2013.05.010     Document Type: Article

References (59)

1. Adamson C.S., Nermut M., Jones I.M. Control of human immunodeficiency virus type-1 protease activity in insect cells expressing Gag-Pol rescues assembly of immature but not mature virus-like particles. Virology 2003, 308:157-165.
2. Alain R. Quantitation of virus particles by negative stain electron microscopy. Microsc. Today 1997, 97:20.
3. Altaras N.E., Aunins J.G., Evans R.K., Kamen A., Konz J.O., Wolf J.J. Production and formulation of adenovirus vectors. Adv. Biochem. Eng. Biotechnol. 2005, 99:193-260.
4. Aucoin M.G., Perrier M., Kamen A.A. Critical assessment of current adeno-associated viral vector production and quantification methods. Biotechnol. Adv. 2008, 26:73-88.
5. Bland J.M., Altman D.G. Comparing two methods of clinical measurement: a personal history. Int. J. Epidemiol. 1995, 24(Suppl. 1):S7-S14.
6. Block O., Mitra A., Novotny L., Dykes C. A rapid label-free method for quantitation of human immunodeficiency virus type-1 particles by nanospectroscopy. J. Virol. Methods 2012, 182:70-75.
7. Caygill R.L., Blair G.E., Millner P.A. A review on viral biosensors to detect human pathogens. Anal. Chim. Acta 2010, 681:8-15.
8. Chang L.J., Zaiss A.K. Lentiviral vectors. Preparation and use. Methods Mol. Med. 2002, 69:303-318.
9. Chen Y., Wu B., Musier-Forsyth K., Mansky L.M., Mueller J.D. Fluorescence fluctuation spectroscopy on viral-like particles reveals variable gag stoichiometry. Biophys. J. 2009, 96:1961-1969.
10. Clark K.R., Voulgaropoulou F., Johnson P.R. A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther. 1996, 3:1124-1132.
11. Cox M.M. Recombinant protein vaccines produced in insect cells. Vaccine 2012, 30:1759-1766.
12. Dale B.M., McNerney G.P., Hubner W., Huser T.R., Chen B.K. Tracking and quantitation of fluorescent HIV during cell-to-cell transmission. Methods 2011, 53:20-26.
13. Deml L., Speth C., Dierich M.P., Wolf H., Wagner R. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol. Immunol. 2005, 42:259-277.
14. DePhillips P., Lenhoff A.M. Pore size distributions of cation-exchange adsorbents determined by inverse size-exclusion chromatography. J. Chromatogr. A 2000, 883:39-54.
15. FDA Guidance for Industry, Bioanalytical Method Validation 2001.
16. Filipe V., Hawe A., Jiskoot W. Critical evaluation of nanoparticle tracking analysis (NTA) by nanosight for the measurement of nanoparticles and protein aggregates. Pharm. Res. 2010, 27:796-810.
17. Frankel A.D., Young J.A. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 1998, 67:1-25.
18. Freed E.O. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998, 251:1-15.
19. Garnier L., Ravallec M., Blanchard P., Chaabihi H., Bossy J.P., Devauchelle G., Jestin A., Cerutti M. Incorporation of pseudorabies virus gD into human immunodeficiency virus type 1 Gag particles produced in baculovirus-infected cells. J. Virol. 1995, 69:4060-4068.
20. Graham F.L., van der Eb A.J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973, 52:12.
21. Hammonds J., Chen X., Zhang X., Lee F., Spearman P. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine 2007, 25:8036-8048.
22. Haynes J.R., Dokken L., Wiley J.A., Cawthon A.G., Bigger J., Harmsen A.G., Richardson C. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 2009, 27:530-541.
23. Hermida-Matsumoto L., Resh M.D. Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging. J. Virol. 2000, 74:8670-8679.
24. Hermle J., Anders M., Heuser A.M., Muller B. A simple fluorescence based assay for quantification of human immunodeficiency virus particle release. BMC Biotechnol. 2010, 10:32.
25. ICH Validation of Analytical Procedures: Text and Methodology Q2(R1) 2005.
26. Joshi S., Joshi R.L. Molecular biology of human immunodeficiency virus type-1. Transfus. Sci. 1996, 17:351-378.
27. Lindwasser O.W., Resh M.D. Myristoylation as a target for inhibiting HIV assembly: unsaturated fatty acids block viral budding. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13037-13042.
28. Ludwig C., Wagner R. Virus-like particles-universal molecular toolboxes. Curr. Opin. Biotechnol. 2007, 18:537-545.
29. Lynch A.G., Tanzer F., Fraser M.J., Shephard E.G., Williamson A.L., Rybicki E.P. Use of the piggyBac transposon to create HIV-1 gag transgenic insect cell lines for continuous VLP production. BMC Biotechnol. 2010, 10:30.
30. Maizel J.V., White D.O., Scharff M.D. The polypeptides of adenovirus, I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968, 36:115-125.
31. McGrath M., Witte O., Pincus T., Weissman I.L. Retrovirus purification: method that conserves envelope glycoprotein and maximizes infectivity. J. Virol. 1978, 25:923-927.
32. Muller B., Daecke J., Fackler O.T., Dittmar M.T., Zentgraf H., Krausslich H.G. Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J. Virol. 2004, 78:10803-10813.
33. Osterrieder N., Wagner R., Brandmuller C., Schmidt P., Wolf H., Kaaden O.R. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology 1995, 208:500-510.
34. Ott D.E. Cellular proteins in HIV virions. Rev. Med. Virol. 1997, 7:167-180.
35. Ott D.E. Potential roles of cellular proteins in HIV-1. Rev. Med. Virol. 2002, 12:359-374.
36. Pease L.F., Lipin D.I., Tsai D.H., Zachariah M.R., Lua L.H.L., Tarlov M.J., Middelberg A.P.J. Quantitative characterization of virus-like particles by asymmetrical flow field flow fractionation, electrospray differential mobility analysis, and transmission electron microscopy. Biotechnol. Bioeng. 2009, 102:11.
37. Pecora A., Perez Aguirreburualde M.S., Rodriguez D., Seki C., Levy M.S., Bochoeyer D., Dus Santos M.J., Wigdorovitz A. Development and validation of an ELISA for quantitation of bovine viral diarrhea virus antigen in the critical stages of vaccine production. J. Virol. Methods 2009, 162:170-178.
38. Perlman M., Resh M.D. Identification of an intracellular trafficking and assembly pathway for HIV-1 gag. Traffic 2006, 7:731-745.
39. Phogat S., Wyatt R.T., Karlsson Hedestam G.B. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J. Intern. Med. 2007, 262:26-43.
40. Pillay S., Meyers A., Williamson A.L., Rybicki E.P. Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system. Biotechnol. Prog. 2009, 25:1153-1160.
41. Roberts G.S., Yu S., Zeng Q., Chan L.C., Anderson W., Colby A.H., Grinstaff M.W., Reid S., Vogel R. Tunable pores for measuring concentrations of synthetic and biological nanoparticle dispersions. Biosens. Bioelectron. 2012, 31:17-25.
42. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Rev. Vaccines 2010, 9:1149-1176.
43. Sakuragi S., Goto T., Sano K., Morikawa Y. HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:7956-7961.
44. Sakuragi S., Sakuragi J., Morikawa Y., Shioda T. Development of a rapid and convenient method for the quantification of HIV-1 budding. Microbes Infect. 2006, 8:1875-1881.
45. Schroder M., von Lieres E., Hubbuch J. Direct quantification of intraparticle protein diffusion in chromatographic media. J. Phys. Chem. B 2006, 110:1429-1436.
46. Schwartz S., Campbell M., Nasioulas G., Harrison J., Felber B.K., Pavlakis G.N. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J. Virol. 1992, 66:7176-7182.
47. Segura M.M., Garnier A., Di Falco M.R., Whissell G., Meneses-Acosta A., Arcand N., Kamen A. Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations. J. Virol. 2008, 82:1107-1117.
48. Segura M.M., Garnier A., Kamen A. Purification and characterization of retrovirus vector particles by rate zonal ultracentrifugation. J. Virol. Methods 2006, 133:82-91.
49. Segura M.M., Monfar M., Puig M., Mennechet F., Ibanes S., Chillon M. A real-time PCR assay for quantification of canine adenoviral vectors. J. Virol. Methods 2010, 163:129-136.
50. Sherer N.M., Lehmann M.J., Jimenez-Soto L.F., Ingmundson A., Horner S.M., Cicchetti G., Allen P.G., Pypaert M., Cunningham J.M., Mothes W. Visualization of retroviral replication in living cells reveals budding into multivesicular bodies. Traffic 2003, 4:785-801.
51. Sutjipto S., Ravindran S., Cornell D., Liu Y.H., Horn M., Schluep T., Hutchins B., Vellekamp G. Characterization of empty capsids from a conditionally replicating adenovirus for gene therapy. Hum. Gene Ther. 2005, 16:109-125.
52. Tagliamonte M., Visciano M.L., Tornesello M.L., De Stradis A., Buonaguro F.M., Buonaguro L. HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. Vaccine 2011, 29:4913-4922.
53. Transfiguracion J., Jaalouk D.E., Ghani K., Galipeau J., Kamen A. Size-exclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications. Hum. Gene Ther. 2003, 14:1139-1153.
54. Transfiguracion J., Mena J.A., Aucoin M.G., Kamen A.A. Development and validation of a HPLC method for the quantification of baculovirus particles. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2011, 879:61-68.
55. Tremblay M.J., Fortin J.F., Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol. Today 1998, 19:346-351.
56. Ulmer J.B., Valley U., Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat. Biotechnol. 2006, 24:1377-1383.
57. Valley-Omar Z., Meyers A.E., Shephard E.G., Williamson A.L., Rybicki E.P. Abrogation of contaminating RNA activity in HIV-1 Gag VLPs. Virol. J. 2011, 8:462.
58. Wilk T., Gross I., Gowen B.E., Rutten T., de Haas F., Welker R., Krausslich H.G., Boulanger P., Fuller S.D. Organization of immature human immunodeficiency virus type 1. J. Virol. 2001, 75:759-771.
59. Yao Q., Bu Z., Vzorov A., Yang C., Compans R.W. Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine 2003, 21:638-643.